Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LXEO with free AI briefings, catalyst countdowns, and dilution alerts.

LXEO · Lexeo Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$234.2M Cash on Hand
36.3mo Cash Runway
Follow LXEO by email Get an email when LXEO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LXEO, unsubscribe in one click. Privacy

📣 What LXEO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
LX1001 Alzheimer Disease Phase 1/2 · NCT03634007 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

LXEO holds $234.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $19.4M/quarter from operations, an estimated runway of 36.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 27 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LXEO files for a raise →

👥 Who Owns LXEO

Insiders 1.1% Other 5%+ holders 4.5% Institutions (197 holders) 94.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
BALYASNY ASSET MANAGEMENT L.P. Institution (13G, 5%+) 8,196,420 9.90% 2026-09-30
Affinity Asset Advisors, LLC Institution (13G, 5%+) 8,112,913 9.80% 2026-09-30
JANUS HENDERSON GROUP Ltd. Institution (13G, 5%+) 5,936,653 7.17% 2026-09-30
SUVRETTA CAPITAL MANAGEMENT, LLC Institution (13G, 5%+) 5,674,778 6.85% 2026-04-06
Kenneth Griffin Institution (13G, 5%+) 5,498,219 6.64% 2025-12-31
Vestal Point Capital, LP Institution (13G, 5%+) 5,187,302 6.27% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 4,885,814 5.90% 2025-12-31
JPMORGAN CHASE & CO. Institution (13G, 5%+) 4,573,701 5.52% 2026-09-30
Frazier Life Sciences Public Fund, L.P. 5%+ holder (13G) 3,698,271 4.47% 2025-12-31
Richard Nolan Townsend
Chief Executive Officer, Director · +792,165 options
Insider 376,778 0.46% 2026-09-24
Jose Manuel Otero
Chief Operating Officer · +314,750 options
Insider 138,288 0.17% 2026-09-24
Louis Edward Tamayo
Chief Financial Officer · +281,415 options
Insider 92,907 0.11% 2026-08-18

Share count 82,788,599 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full LXEO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LXEO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.